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Abstract Background Factor VIII (FVIII) products are usually dosed according to body weight
(BW). This may lead to under- or over-dosing in underweight or obese patients,
respectively.
Objective This article evaluates the pharmacokinetics (PK) of recombinant FVIII
concentrate, particularly recovery, in relation to body mass index (BMI) and other
body composition descriptors.
Materials and Methods Thirty-five previously treated adults with severe haemophilia
A from five BMI categories (underweight, normal, overweight, obese class I and II/III)
were included. PK was evaluated after 50 IU per kilogram of BW single-dose recombi-
nant FVIII (turoctocog alfa). The body composition variable was based on measure-
ments of weight, height, bioimpedance analysis, and dual-energy X-ray
absorptiometry. A dosing model was derived to achieve similar peak FVIII activity
levels across BMI categories.
Results A statistically significant positive association between BMI and C30min,
IR30min, and AUC0–inf was observed; CL and Vss showed a significant negative associa-
tion with BMI; t½ was independent of BMI and other parameters. The dosing model
introduced a correction factor ‘M’ for each BMI category, based on linear regression
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Introduction
Factor VIII (FVIII) products have a long-standing and well-
established role in the treatment of haemophilia A as
long-term prophylaxis to protect against bleeding episodes,
for on-demand treatment to control a bleed or for providing
haemostatic cover for surgery.1 Correct dosing of FVIII is crucial
to avoid under-dosing, which may lead to inadequate bleed
control, or overdosing leading to a waste of FVIII product.2
FVIII products are typically dosed according to total body
weight (BW),2,3 meaning that heavier patients receive a
proportionally higher drug dose than patients with normal
weight.4 The growing population of overweight and obese
patients with haemophilia is a clinical concern,3,5 and
arthropathy occursmore commonly in overweight and obese
patients with haemophilia;6 though it is unclear why joint
disease is increased in this patient population.4
FVIII is primarily distributed in plasma, with only a small
fraction (14%) circulating outside the vascular system.1 The
ratio of plasma volume to BW usually decreases with increas-
ing severity of obesity,7 as increased BW is accounted for by
more fatty tissue, which contains less blood volume than
muscle of the same weight.6 Overweight/obese individuals,
therefore, typically have a lower plasma volume per kilogram
of BW, while underweight individuals have a higher plasma
volume per kilogram of BW than normal-weight individuals.
Hence, weight-based dosing of FVIII would introduce a sys-
tematic error of unknownmagnitude andmaynot result in the
desired FVIII plasma levels in people with varying BW and/or
body compositions. It has been suggested that dosing should
consider fat mass as well as BW.2
Few studies have investigated the impact of different
morphometric parameters on FVIII pharmacokinetics
(PK),8–12andclinicalguidance for thedosingof FVIII inpatients
with haemophilia according to body composition is lacking.
Data from a PK trial with the recombinant FVIII (rFVIII)
turoctocog alfa (NovoEight, Novo Nordisk, Bagsværd,
Denmark) in a small subset of patientswith a bodymass index
(BMI) 30 kg/m2 indicated that typical weight-based dosing
leads to higher post-dose FVIII levels in overweight/obese (vs.
normal-weight) patients.13
Here, we report the findings of a larger PK trial that
assessed whether a relationship between PK (particularly
recovery) and body composition could be identified and
utilised to improve the predictability of plasma FVIII activity
after treatment with turoctocog alfa in a dosing model.
Materials and Methods
Trial Objectives and Endpoints
The primary objective of the trial was to evaluate the single-
dose PK (particularly recovery) of turoctocog alfa in relation
to BMI in patients with severe haemophilia A. Secondary
objectives were to evaluate the single-dose PK of turoctocog
alfa in relation to other BW and composition variables as
potential PK predictors, and to add to the established safety
record of turoctocog alfa.
The primary PK endpoint was FVIII activity at 30minutes
(C30min). Key secondary PKendpoints comprised incremental
recovery at 30minutes (IR30min), area under the FVIII activity
time curve from 0 to infinity (AUC0–inf), terminal half-life
(t½), clearance per kilogramof BW (CL), and apparent volume
of distribution per kilogram of BW at steady state (Vss)
(►Supplementary Material, available in the online version).
The safety endpoint was the number of adverse events (AEs)
up to day 28.
Patients
Malepatientsaged 18yearswithseverehaemophiliaA (FVIII
activity< 1%) and> 150 exposure days to FVIII products were
included. Patients with a current/past history of FVIII inhib-
itors (0.6BethesdaUnits) or anyknowncoagulationdisorder
(apart from haemophilia A) were excluded. At visit 1, BMIwas
calculated based on BW and height. Patients were then
grouped intofiveBMI categories: underweight (< 18.5 kg/m2),
normal (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), obese
class I (30–34.9 kg/m2), or obese class II/III ( 35 kg/m2).
Recruitment was stratified by BMI group to ensure a balance
between the five categories.
Trial Design
The PK trial was a multi-national, multi-centre, open-label,
single-arm trial investigating the single-dose PK of turoctocog
alfa in relation to BMI in previously treated adults with severe
haemophilia A without inhibitors. The trial was conducted
between October 2016 and June 2017 at 13 sites in seven
countries (Austria, Bulgaria, Germany, Serbia, Spain, Taiwan
and the United States).
Turoctocog alfa was supplied as a sterile, freeze-dried
powder in single-use vials and reconstituted in 4.3mL of
0.9% sodium chloride prior to intravenous injection. Total
trial duration for each patient was 28 days, excluding a
screening period of 28 days. The trial included one PK
session per patient. There were six planned visits: one
obese class II/III. This model achieved similar peak FVIII activity levels across BMI
categories, estimating an average dose adjustment of þ243.3 IU (underweight) to
–1,489.6 IU (obese class II/III) to achieve similar C30min.
Conclusion BMI appears to be the best predictor of recombinant FVIII recovery;
however, PK endpoints were also dependent on other body composition variables. The
model demonstrated that dosing can be adjusted for individual BMI to achieve better
FVIII predictability across BMI categories.
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screening visit (visit 1); one 72-hour PK session with four
visits (visits 2–5); one follow-up visit (visit 6) that took place
28 7 days after visit 2. At visit 2, each patient received a
single intravenous bolus injection of turoctocog alfa at 50 IU
per kilogram of BW in a non-bleeding state after a 96-hour
washout period for FVIII-containing products. PK sampling
was performed 11 times between –1 hour (i.e., pre-dose) and
72 hours.
The trial was approved by independent ethics committees
and institutional review boards, and was conducted in
accordance with the Declaration of Helsinki14 and Good
Clinical Practice guidelines.15 Written informed consent
was obtained from all patients prior to any trial-related
activity. The trial (NCT02941354) was registered at www.
clinicaltrials.gov.
Pharmacokinetic Assessments
Bloodsamples forPKanalysiswere collectedpre-dose, at15and
30minutes and 1, 3, 6, 9, 24, 28, 48 and 72 hours post-dose. PK
endpointswere calculated using FVIII activity andmeasured by
one-stage clotting (activated partial thromboplastin reagent,
SynthASil [Instrumentation Laboratory, Milan, Italy]) and chro-
mogenic (Coamatic FVIII kit [Instrumentation Laboratory])
assays performed on a Coasys Plus C analyser (Roche Diagnos-
tics,Mannheim,Germany).16Humanplasmastandard, calibrat-
ed against World Health Organization international FVIII
standards, was used to calibrate both assays. All PK-derived
parameterswere determined using non-compartmentalmeth-
ods, as such methods are consistent with previous studies,16,17
simple to use and require no assumptions to be made.
Measures of Body Composition and PK Predictors
Measurements of body composition and other potential
predictors (ideal BW [IBW], body surface area, lean BW,
adjusted BW based on fat-free mass measurements from
bioimpedance analysis [BIA], predicted blood volume) were
investigated for their association with PK parameters based
on the chromogenic assay.
Measurements of body composition: Body composition
was measured at either visit 3, 4 or 5 using dual-energy X-
ray absorptiometry (DXA) and BIA. Where possible, both
measurements were taken at the same visit. Thewhole-body
DXA scan, conducted at a local imaging site, measured total
fat mass, lean body mass and body fat percentage. BIA,
conducted at the trial site using a Tanita DC 430 SMA Body
Composition Analyzer (Tanita Corporation, Tokyo, Japan)
supplied by Novo Nordisk, measured total fat mass, fat-free
mass and body fat percentage. The average of two measure-
ments was used for each parameter to reduce variability.
In addition to the abovemeasurements, body composition
variables were calculated using formulae based on BW
and/or height measurements (►Table 1).
Relationship between coagulation parameters and BMI:
The influence of BMI on different coagulation parameters,
namely pro-thrombin time, pro-thrombin fragment 1þ 2,
von Willebrand factor (vWF), plasminogen activator inhibi-
tor-1 (PAI-1) and plasmin-a2-antiplasmin (PAP) complex,
was investigated.
Relationship between t½, blood group and vWF: The relation-
ship between t½, blood group and vWF was also determined.
Statistical Methods
There were no formal statistical power calculations with
respect to sample size. Thirty-five patients were planned to
be included in the trial so that 6 1 patients could be
included in each of the five BMI categories at baseline. All
dosed patients with data after dosing were included in the
full and safety analysis sets.
Primaryanalysis comprised a linear regression of the prima-
ry endpoint (C30min) against BMI (BMI was treated as a contin-
uous variable). Alternative parametric functional models for
C30min were also explored as part of the primary analysis,
covering quadratic and linear regression on logarithm-trans-
formedpredictors.No formalhypotheseswere tested;however,
linearity was determined by fitting linear, quadratic and log-
linear models, and comparing the R2 for these models to assess
goodness-of-fit;p-values assessedstatistical significance.Other
conditions of validity (homoscedasticity and outlier assess-
ment) were also evaluated by visual inspection. C30min was
also analysed using measured and calculated predictors in the
regression analyses. Measured predictors were body fat per-
centage (measuredbyDXAandBIA), leanbodymass (measured
by DXA), fat-free mass (measured by BIA) and total body fat
(measured by DXA and BIA). The mean of two measurements
was used for all BIA assessments, unless only onewas available.
Calculated predictors comprised IBW, body surface area, lean
BW,adjustedBWandpredictedbloodvolume.A selectionof the
analyses conducted for the primary endpoint (C30min) was also
conducted for the secondary PKendpoints (IR30min, AUC0–inf, t½,
CL andVss); all analyseswith t½were adjusted for age andblood
group (O and Non-O). Non-compartmental analysis of PK data
was performed using SAS (version 9.4; SAS Institute Inc., Cary,
North Carolina, United States), using code made to mimic
algorithms used in Phoenix WinNonlin (Certara, Princeton,
New Jersey, United States).
All AEs were summarised and listed.
Table 1 Formulae for key calculated predictors
Parameter Formula
BMI (kg/m2) BMI¼weight (kg)/[height (m)]2
IBW (kg)2 IBW¼ height (cm) 100–[height (cm) – 150]/4
BSA (m2)18 BSA¼ BW0.425 height in cm0.725 0.007184











Abbreviations: ABW, adjusted body weight; BIA, bioimpedance analysis;
BMI, body mass index; BSA, body surface area; BW, body weight; BV,
blood volume; FFM, fat-free mass; IBW, ideal body weight; LBW, lean
body weight; PBV, predicted blood volume.
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Dosing Model
The required FVIII dose for on-demand treatment is currently
determined using the following formula: dose¼ BW
(kg) 100 (as desired level is 1 IU/mL) 0.5.21,22 This formula
indicates that, for a patient to have a C30min of 1 IU/mL at
complete washout (1 IU/mL relates to 100% FVIII activity [i.e.,
normal levels]), the dose should be 50 IU per kilogram of BW.
The proposed new dosing model derived from the results of
the current trial used C30min (as the goalwas to achieve similar
peak FVIII activity levels across BMI categories) and BMI,
because the regression for BMI gave the largest R2 values
among the tested predictors; thus, a model using BMI has
the largest potential to reduce variability in C30min. Therefore,
the new dosing model was based on linear regression of FVIII
activity at 30minutes, measured using the one-stage clotting
assay, with BMI as a continuous predictor. The one-stage
clotting assay was used because it is more commonly used
for routine FVIII monitoring. The dosing model used the
following formula:
where ‘M’ is the correction factor for dosing that is expected
to provide similar C30min across patients with different BMI.
‘M’ was in the following form:
where X is the average BMI in this trial for a given BMI
category and were the intercept and slope parameter
estimates obtained from a linear regression analysis of
C30min against BMI and scaled so that a desired FVIII rise of
100% corresponded to the average FVIII activity in the normal
BMI category. Further details of how linear regression was
used to calculate the correction factor (‘M’) and thus estab-
lish the new dosing model are provided in the
►Supplementary Material (available in the online version).
The reference value for C30min (based on the one-stage
clotting assay) was the mean value across all normal-weight
patients in the trial. With this, it was intended that the
proposed dosing model would give similar C30min values
after dosing with turoctocog alfa across all BMI categories
and irrespective of other descriptors of body composition in
patients with haemophilia A. The dosing model was
assessed by scaling the original data according to the new
dosing model (►Supplementary Material, available in the
online version) and re-analysing the relationship between
PK and body measurements.
Results
Patients
Thirty-five patients received a single dose of turoctocog alfa.
The overall mean agewas 37.4 years (range: 23.0–57.0 years);
mean ageswere similar across all BMI categories. Themajority
of patientswerewhite (N¼ 32 [91.4%]). Patient demographics
and baseline characteristics are shown in ►Table 2.
Pharmacokinetics
FVIII activity: FVIII activity profiles showed an expected
exponential decline over time with a clear trend of increas-
ing FVIII activity levels from underweight to obese class
II/III patients. The summary of key PK endpoints (based on
the chromogenic assay) by BMI category is presented
in ►Table 3.
Association of C30min and AUC0-inf with Measurements
of Body Composition
C30min, the primary PK endpoint, was found to have a
significant positive linear association with measurements
of body composition, namely body fat percentage, lean body
mass, fat-free mass and total fat mass (all measured by DXA
and BIA) (►Supplementary Table S1, available in the online
version). Chromogenic and one-stage clotting assays
yielded similar results in the statistical analyses of depen-
dencies. While all measurements were significant predic-
tors of C30min, none had a higher R2 value (indicating how
predictive each association is) than BMI, suggesting that
BMI is the best predictor of PK endpoints (►Fig. 1A). The R2
values associated with BIA measurements tended to be
higher than those associated with DXA measurements,
suggesting that BIA measures give better prediction of PK
endpoints than DXA. A statistically significant positive
association between AUC0-inf and BMI was also observed
(►Fig. 1B), as well as with several other measurements
(►Supplementary Table S1, available in the online version).
Quadratic- and logarithm-transformed models did not add
any additional information beyond that provided by the
linear model. The association of other PK endpoints with
measured predictors is provided in the ►Supplementary
Material and ►Supplementary Table S1 (available in the
online version).
Association of PK Endpoints with BMI
All results in this section are based on FVIII measurements
derived from the chromogenic assay. Similar results for the
primary and secondary endpointswere obtainedwhen using
the one-stage clotting assay.
C30min: A statistically significant positive association
between C30min and BMI, in which C30min values increased
with increasing BMI, was observed. The geometric
mean C30min values ranged from 1.24 IU/mL (coefficient
of variation [CV]: 17.3%) in the underweight group to
1.96 IU/mL (CV: 13.2%) in obese class II/III patients
(►Table 3; ►Fig. 2A).
IR30min: A statistically significant positive association
between IR30min (derived from C30min) and BMI was
observed. The geometric mean IR30min increased from
0.022 (IU/mL)/(IU/kg) (CV: 17.7%) in underweight patients
to 0.035 (IU/mL)/(IU/kg) (CV: 13.3%) in obese class II/III
patients (►Table 3; ►Fig. 2B).
AUC0–inf: A statistically significant positive association
between AUC0-inf and BMI was also observed. The geometric
mean AUC0-inf values ranged from 17.8 IU h/mL (CV: 32.5%)
in underweight patients to 29.7 IU h/mL (CV: 25.6%) in
obese class II/III patients (►Table 3; ►Fig. 2C).
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t½: The geometric mean ranged from 9.2 hours (CV: 35.2%)
to 11.5 hours (CV: 21.2%) across the BMI categories (►Table 3)
andwas found to be independent of BMI (►Fig. 2D) and other
predictors (►Supplementary Table S1, available in the online
version). In addition, there was no relationship between BMI
and the time to 1% of normal FVIII activity (►Supplementary
Table S2 and►Supplementary Fig. S1 [available in the online
version]).
CL: Derived from AUC0-inf, CL showed a significant nega-
tive association with BMI, as expected. Underweight and
obese class II/III groups showed a geometric mean CL of 3.16
(CV: 33.1%) and 1.88mL/h/kg (CV: 25.7%), respectively
(►Table 3; ►Fig. 2E).
Vss: A significant negative association between Vss per
kilogram of BWand BMIwas observed. The highest geometric
mean Vss was found in the underweight group (48.1mL/kg
[CV: 22.3%]) and the lowest in the obese class II/III patients
(25.4mL/kg [CV: 16.0%]) (►Table 3; ►Fig. 2F).
Association of C30min with Body Surface Area, Lean
BW, Adjusted BW and Predicted Blood Volume
Weobserved a significantly positive association of C30min and
derived parameter IR30min with most potential predictors of
PK parameters, namely body surface area, lean BW, adjusted
BW and predicted blood volume (►Supplementary Table S1,
available in the online version). However, there was no
significant association of C30min with IBW (p¼ 0.8801; R2:
0.0007) (►Fig. 1C) and AUC0-inf with IBW (p¼ 0.7706; R2:
0.0026) (►Fig. 1D). The R2 values for PK predictors were all
lower than that for BMI and most other body composition
measurements. As with the assessments, quadratic- and
logarithm-transformed models of calculated predictors did
not add any additional information beyond that provided by
the linear model. The association of other PK endpoints with
body surface area, lean BW, adjusted BWand predicted blood
volume is provided in the ►Supplementary Material (avail-
able in the online version).













N 5 7 9 7 7 35
Age (y)
Mean (SD) 34.0 (8.9) 42.4 (11.0) 34.4 (11.4) 35.9 (10.6) 40.3 (8.1) 37.4 (10.2)
Race, N (%)
White 5 (100.0) 5 (71.4) 8 (88.9) 7 (100.0) 7 (100.0) 32 (91.4)
Asian 0 (0.0) 1 (14.3) 1 (11.1) 0 (0.0) 0 (0.0) 2 (5.7)
Black or African American 0 (0.0) 1 (14.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.9)
Height (m)
Mean (SD) 1.81 (0.07) 1.70 (0.09) 1.74 (0.10) 1.76 (0.10) 1.78 (0.06) 1.76 (0.09)
BW (kg)
Mean (SD) 55.26 (5.86) 63.14 (5.95) 82.98 (12.5) 102.3 (12.7) 131.9 (17.4) 88.69 (29.3)
BMI (kg/m2)
Mean (SD) 16.78 (0.77) 21.77 (1.61) 27.12 (1.78) 33.06 (2.04) 41.41 (4.86) 28.62 (8.65)
BFP (%, DXA)
Mean (SD) 17.2 (6.4) 27.1 (8.7) 28.9 (8.3) 35.1 (6.9) 44.7 (8.7) 30.9 (11.3)
BFP (%, BIA)
Mean (SD) 14.1 (6.4) 23.2 (5.2) 25.2 (3.6) 32.2 (3.0) 42.1 (3.8) 27.7 (9.8)
IBWa (kg)
Mean (SD) 73.4 (5.01) 65.3 (7.11) 68.3 (7.40) 69.3 (7.50) 71.3 (4.72) 69.2 (6.74)
BSAa (m2)
Mean (SD) 1.7 (0.12) 1.7 (0.13) 2.0 (0.20) 2.2 (0.20) 2.5 (0.17) 2.0 (0.32)
LBWa (kg)
Mean (SD) 49.6 (4.50) 51.7 (4.96) 61.3 (7.95) 68.5 (7.82) 78.2 (6.09) 62.5 (12.10)
ABWa (kg)
Mean (SD) 50.6 (4.56) 54.4 (5.29) 68.8 (9.36) 82.1 (8.53) 101.0 (12.44) 71.7 (19.68)
PBVa (L)
Mean (SD) 4.4 (0.38) 4.5 (0.43) 5.2 (0.67) 5.8 (0.67) 6.7 (0.56) 5.4 (1.01)
Abbreviations: ABW, adjusted bodyweight; BFP, body fat percentage; BIA, bioimpedance analysis; BMI, bodymass index; BSA, body surface area; BW, body
weight; DXA, dual-energy X-ray absorptiometry; IBW, ideal body weight; LBW, lean body weight; PBV, predicted blood volume; SD, standard deviation.
aSee ►Table 1 for formulae for calculated predictors.
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Coagulation Parameters and BMI
Wefoundnoassociationbetween coagulationparameters (i.e.,
pro-thrombin time, pro-thrombin fragment 1þ 2, vWF and
PAP [data not shown]) and BMI. However, increased levels of
PAI-1 in obese class II/III patients were observed.
Relationship between t½, Blood Group and vWF
We observed a trend of decreasing t½ with decreasing
vWF antigen levels, with a large variation in t½ and
vWF levels (►Fig. 3A). Additionally, patients with blood
group O tended to have a shorter t½ than patients with
other blood groups (►Fig. 3B). Adjusting for BMI did
not change the significant influence of vWF on t½ (data
not shown).
Dosing Model
The above PK results were used to derive a new dosingmodel
showing the potential for dose adjustments that would
produce more uniform C30min values across BMI categories.
The dosing model used the following formula:
where ‘M’ is the correction factor for dosing that is expected
to provide similar C30min across patients with different BMI:
• Underweight: 0.55
• Normal weight: 0.51
• Overweight: 0.47
• Obese class I: 0.43
• Obese class II/III: 0.39
Between-patient variation in C30min was reduced by 40.5%,
and between-patient variation for AUC0-inf was reduced by
26.4%. The observed total dose based on an administered dose
of50 IUperkilogramofBWandthenewtotaldosebasedonthe
model by BW and BMI category are shown in ►Table 4, along
with potential dosing adjustment based on the model; the
mean total dose adjustment varied from þ243.3 IU in under-
weightpatients to–1489.6 IU inobeseclass II/III patients.None
of the other investigated PK predictors further improved the
dosing model.
Safety
No inhibitor development or AEs leading to death or with-
drawalwere reported, and no newsafety concerns (including
no adverse drug reactions) were observed.
Discussion
The current trial was conducted to investigate the single-
dose PK of the rFVIII turoctocog alfa in relation to BMI in












N 5 7 9 7 7
C30min (IU/mL)
Geometric mean (CV%) 1.24 (17.3) 1.65 (9.4) 1.66 (15.9) 1.79 (15.1) 1.96 (13.2)
Range 1.02–1.58 1.47–1.90 1.32–2.02 1.46–2.31 1.59–2.28
IR30min (IU/mL)/(IU/kg)
Geometric mean (CV%) 0.022 (17.7) 0.029 (9.5) 0.029 (16.0) 0.032 (15.5) 0.035 (13.3)
Range 0.018–0.028 0.026–0.034 0.023–0.036 0.026–0.041 0.028–0.041
AUC0–inf (IU h/mL)
Geometric mean (CV%) 17.8 (32.5) 26.1 (33.6) 21.3 (44.1) 24.9 (58.0) 29.7 (25.6)
Range 14.0–30.9 17.1–40.4 13.3–39.0 11.0–41.1 19.0–42.4
t½ (h)
Geometric mean (CV%) 11.5 (21.2) 10.9 (38.5) 9.2 (35.2) 9.9 (38.1) 10.3 (21.7)
Range 8.3–15.0 5.7–15.3 5.8–15.5 5.2–13.6 8.3–15.4
CL (mL/h/kg)
Geometric mean (CV%) 3.16 (33.1) 2.15 (33.3) 2.64 (44.3) 2.25 (58.6) 1.88 (25.7)
Range 1.80–4.03 1.37–3.30 1.44–4.28 1.36–5.17 1.31–2.94
Vss (mL/kg)
Geometric mean (CV%) 48.1 (22.3) 31.0 (15.0) 31.1 (18.6) 28.5 (17.9) 25.4 (16.0)
Range 35.3–61.1 24.0–36.9 23.0–41.1 22.3–37.3 19.1–32.5
Abbreviations: AUC0–inf, area under the FVIII activity-time curve from 0 to infinity; BMI, body mass index; C30min, FVIII activity at 30 minutes; CL,
clearance; CV, coefficient of variation; IR30min, incremental recovery at 30 minutes; PK, pharmacokinetics; SD, standard deviation; t½, terminal half-
life; Vss, apparent volume of distribution at steady state.
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previously treated adults with severe haemophilia A, with a
focus on recovery. Overall, the trial showed increased C30min,
AUC0–inf and IR30min with increasing BMI, while CL and Vss
decreased with increasing BMI. Of all the measured and
calculated predictors assessed (IBW, body surface area,
lean BW, adjusted BW and predicted blood volume), BMI
was the most robust and best predictor of PK endpoints. The
exception to this was t½, which seemed to be independent of
all predictors.
The Dosing Model
The combined BW and BMI dosing model resulted in predict-
able PK parameters in patients with different body composi-
tions. The innovative component of the dosing model was
incorporation of the correction factor ‘M’ to calculate dosage
adjustments based on the difference in C30min across five BMI
categories. The model reduced total variation by 40.5% for
C30min andby26.4% forAUC0-inf.Nootherpredictorsignificantly
improved the dosing model beyond the addition of BMI (data
not shown). The new dosing model also indicates that, when
using current standarddose calculations, underweight patients
might receive an insufficient FVIII dose for effective bleed
control, overweight/obese patients might receive more FVIII
thanneededandnormal-weightpatientswouldrequire littleor
no dose adjustment comparedwith the current dosing recom-
mendation (►Table 4).
Why BMI Performs Well as a Predictor of FVIII PK
IBW has been suggested instead of actual BW for FVIII dose
calculations.10,11 A recent study performed on simulated
patients found that dosing based on IBW was cost effective
and provided the highest proportion of time spent above 1%
FVIII on standard prophylaxis.3 In contrast, in the current
trial, which included real patients and measured PK param-
eters, IBW was not found to be a useful metric for FVIII dose
adjustment when the goal is to achieve uniform PK across
weight categories. IBW is directly correlated to height and is
not based on any aspect of body composition or weight. In
the current trial, IBW was the only predictor that did not
show any association with any PK endpoints. A possible
explanation for BMI being a good predictor of PK endpoints
might be that the trial participants had body compositions
(i.e., proportions of highly vascularised, lean tissue vs. poorly
vascularised, fatty tissue) that were typical of their BMI
category. In this way, some fatty tissues are accounted for
by BMI, whereas IBW would completely ignore the fatty
tissue and thereby over-adjust the dose. FVIII recovery has
been found to increase with increasing BMI and BW.9,11,23 A
regression-tree analysis conducted by Henrard et al to
examine the impact of various morphometric parameters
(different parameters to those chosen in the current trial) on
FVIII recovery among 201 adults (> 18 years) with haemo-
philia A found BMI to be the strongest predictor of FVIII
Fig. 1 C30min and AUC0–inf versus BMI and IBW (chromogenic assay). (A) C30min showed significant positive associations with BMI (linear
regression line, p< 0.0001; R2: 0.5086). (B) AUC0–inf showed significant positive associations with BMI (linear regression line, p< 0.0263; R
2:
0.1409). (C) IBW was not associated with PK endpoints; linear regression line, p¼ 0.8801 for C30min; R2, 0.0007 is from the linear regression
model; and (D) linear regression line, p¼ 0.7706 for AUC0–inf; R2, 0.0026. AUC0–inf, area under the activity–time curve from 0 to infinity; BMI,
body mass index; C30min, FVIII activity at 30 minutes; IBW, ideal body weight; PK, pharmacokinetic.
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Fig. 2 C30min, IR30min, AUC0–inf, t½, CL and Vss by BMI category (chromogenic assay). Statistically significant positive association between BMI
and (A) C30min, (B) IR30min and (C) AUC0–inf; lack of association between BMI and (D) t½; statistically significant negative association between BMI
and (E) CL and (F) Vss. The box and whisker plots are based on standard non-parametric measures, and the circles represent arithmetic means.
Arithmetic mean C30min ranged from 1.25 to 1.98 IU/mL in underweight to obese class II/III patients, respectively. Individual C30min ranged from
1.02 to 2.31 IU/mL. BMI, body mass index; BW, body weight; C30min, FVIII activity at 30 minutes; IR30min, incremental recovery at 30 minutes; Vss,
apparent volume of distribution per kilogram of BW at steady state. BMI categories are derived from BMI calculated at screening: underweight
(BMI< 18.5 kg/m2), normal range (BMI: 18.5–24.9 kg/m2), overweight (BMI: 25–29.9 kg/m2), obese class I (BMI 30–34.9 kg/m2) and obese class
II/III (BMI  35 kg/m2).
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recovery, in line with current findings.11 The regression-tree
analysis also found significantly different (p< 0.001) median
FVIII recovery values of 1.60, 2.14 and 2.70 among patients
with BMI< 20.3, 20.3 to 29.5 and 29.6 kg/m2, respectively.
Exploring the Measures of Body Composition
AlthoughDXAcanmeasure fat andmuscle compartments,24,25
BIA body composition measurements gave slightly better
predictions (R2) of PK parameters than DXA measurements
in the current trial, which is unexpected. As FVIII activity is
primarily distributed in blood, the BIA assessment may have
performed better than DXA due to the dependency of BIA on
the body’s fluid content (including blood). BIA measurements
can also be affected by factors such as physical activity,
hydration status and consumption of food and beverages.24
To limit the interference of these factors in the current trial,
patients were advised to drink fluid normally during the
24 hours prior to the scan (2 L), avoid alcohol consumption
(within 12 hours prior to the scan), avoid large meals (within
4–6 hours prior to the scan) and were asked to empty their
bladder prior to the scan.
Measures of fat and lean mass directly obtained by DXA
and BIA performed weaker as predictors of FVIII PK than the
measurements of BMI. This may be explained by the fact that
these measures account for lean or fatty tissue but not for
both, while blood is unequally distributed in both tissues.
Relationship of BMI to t½, Blood Group and vWF
Increased adipose tissues in obese patients might contribute
to the release of adipokines and cytokines, resulting in
changes in coagulation factor levels in the liver.26,27 Consid-
ering this, the influence of BMI on different coagulation
parameters in the current trial was explored. However, no
influence of BMI on coagulation parameters was seen, except
increased PAI-1 levels in the obese class II/III patients versus
Fig. 3 t½ versus vWF (A) and blood group (B) (chromogenic assay) t½
versus blood group is a box plot (B), ‘þ ’ represents the mean and the
horizontal lines within the box represents the median. t½, terminal
half-life; vWF, von Willebrand factor.













N 5 7 9 7 7
Observed dose (IU)
Mean dose (SD) 2,780.2 (277.4) 3,214.1 (279.8) 4,201.7 (622.5) 5,144.1 (639.2) 6,642.9 (838.1)
New dose using dosing model
Mean dose (SD) 3,023.5 (282.5) 3,216.3 (302.9) 3,890.9 (515.7) 4,424.5 (508.4) 5,153.3 (429.8)
Change from observed
Mean (SD) 243.3 (25.3) 2.2 (84.5) –310.7 (126.4) –719.6 (182.5) –1,489.6 (469.1)
Correction factor (M) 0.55 0.51 0.47 0.43 0.39
Abbreviations: BMI, body mass index; M, the correction factor to dosing that is expected to provide similar C30min across patients with different BMI
(i.e., the factor for multiplication with body weight to obtain the dose that is predicted to give the same C30min from the one-stage clotting assay as
the average in the normal BMI category in this study); SD, standard deviation.
Note: Dosing model was based on linear regression results for one-stage clotting assay versus BMI. Results from the one-stage clotting assay were
used for the dosing model as these seemed the most relevant, showing the greatest decrease in standard deviation (vs. results using the
chromogenic assay).
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non-obese patients, consistent with a study that also found
elevated PAI-1 levels in obese individuals, possibly indicating
reduced fibrinolysis in this group.5
When investigating the relationship between t½, blood
group and vWF, we found a large variation of t½ and vWF
antigen levels. Nevertheless, t½ appeared to decrease with
decreasing vWF levels, which would be expected based on
the tight association between FVIII and vWF; vWFmaintains
FVIII stability and prevents its degradation and CL.28 Patients
with blood group O have lower vWF levels than those with
other blood groups.29As expected, patientswith blood group
O in the current trial had lower vWF levels and therefore a
shorter t½ than patients with other blood groups.
Limitations
The study showed an impact of BMI on peak levels after
dosing, but not on t½. Achieving certain peak levels is
primarily relevant for managing surgery or acute bleeds in
patients with haemophilia. Routine prophylaxis, however,
targets certain trough levels that are mainly influenced by
individual t½. Therefore, our data, including the new dosing
model, are not relevant for routine prophylaxis dosing.
Chromogenic and one-stage clotting assays yielded simi-
lar results in the PK assessments, although there was a shift
in FVIII concentration values between the two assays. As the
chromogenic assay provided more stable results and led to
exclusion of fewer samples than the one-stage assay, results
obtained with the chromogenic assay have been presented
for PK analyses. However, results from the one-stage clotting
assay (more commonly used for routine FVIII monitoring)
were used for the dosing model as they showed the greatest
decrease in standard deviation (vs. results using the chro-
mogenic assay); hence, we presented results based on the
one-stage assay for the dosing model.
Given the negative association observed between age and
dose requirement in the literature,30 lackof adjustment for age
in the current study may also be a potential limitation of our
findings; age did not affect C30min, AUC andCL, but the range of
ages in the current trial may have been too small to show
differences.
Another limitationof thetrialwas that thestudypopulation
did not include extremely underweight patients (for example,
elderly individuals or those with low fat mass) or extremely
muscular individuals (such as body builders and athletes) or
severely anaemic patients (to factor haematocrit levels);
hence, the results are only applicable to a population with
similar attributes. There is a need to validate the model in all
BMI populations. BMI may be a poorer predictor of FVIII PK in
patients with differing body compositions (e.g., those with
greatermusclemass). However, highBMI due toa highvolume
of muscle mass is rare in patients with severe haemophilia.
Finally, some studies found two-compartmental analysis
superior to non-compartmental analysis (e.g., Björkman
et al31), while others did not (e.g., Morfini et al32). For turocto-
cog alfa PK data, there was no clear distribution phase or
divergent trend regarding observed PK overlaidwith predicted
PK based on non-compartmental methods. As such, non-com-
partmental analysis had a good fit for turoctocog alfa PK data.
Conclusion
The trial confirmed that the PK of FVIII (C30min, AUC, IR30min,
CL and VSS) depends on BMI and body composition. A
statistically significant positive association between C30min
and BMI, and between C30min and body surface area, lean BW,
adjusted BW and predicted blood volume, was observed.
Furthermore, of the parameters assessed in the trial, BMIwas
found to be the best predictor of PK endpoints, except for t½,
which appears to be independent. We also propose a novel
and simple dosing model, which allowed improved predict-
ability of plasma FVIII activity after treatment with rFVIII
across all BMI categories. The dosing model introduced a
correction factor ‘M’ for each BMI category ranging from 0.55
for underweight to 0.39 for obese class II/III. Future studies to
explore the relationship between FVIII activity levels and
clinical efficacy are warranted.
What is known about this topic?
• FVIII products are typically dosed on a per-kilogram
basis according to total body weight.
• Therapeutic FVIII administration based solely on body
weight leads to varying FVIII levels.
• Few studies have investigated the impact of different
morphometric parameters on FVIII PK, and clinical
guidance for the dosing of FVIII in patients with
haemophilia according to body composition is lacking.
What does this paper add?
• Pharmacokinetics of recombinant FVIII administration
in persons with varying BMI was assessed in a single-
dose PK trial.
• C30min, IR30min, AUC0–inf correlated with BMI, whereas
t½ did not.
• Of several morphometric parameters assessed, BMI
best predicted incremental recovery.
• Body weight- and BMI-based model allowed dosing
with better FVIII predictability across BMI categories.
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